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Abstract
Several approaches have been developed to overcome historical barriers associated with poor outcomes in the setting of
HLA-haploidentical allogeneic transplantation (HaploSCT). Here, we examine the outcome of patients with various
hematological disorders undergoing HaploSCT with high-dose, post-transplantation cyclophosphamide. We performed a
retrospective study on 381 patients from 30 centers between January 2013 and December 2015. At the last follow-up, a total
of 1058 infectious episodes were diagnosed, affecting 90.3% of the cohort. Median time to ﬁrst infection was 13 days for
bacterial, 32 days for viral and 20 days for fungal infections. Around 41% of these infections were of bacterial origin and
35% of viral origin, among which 48.8% of patients presented CMV reactivation. Median of GVHD relapse-free survival,
progression-free survival and overall survival were 7.1 months, 19.9 months and 33.5 months, respectively. HSCT
procedure was the primary or contributing cause of death (55.6%), followed by relapse of the original disease (34.2%).
Infections accounted for 45.7% of the HSCT-related deaths. The present multicenter data on a large cohort of patients
receiving HaploSCT with PTCy conﬁrmed the feasibility of the procedure with an acceptable incidence of infectious
complications, not different as compared to other haploidentical platforms or HLA-matched transplantation.
Introduction
Pioneer attempts of haploidentical stem cell transplantation
(HaploSCT) following myeloablative conditioning and
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combined with a standard graft-vs.-host disease (GVHD) pro-
phylaxis were characterized by an intense bidirectional allor-
eactivity which in turn induced a high incidence of graft failure,
GVHD development and treatment-related mortality [1]. To
overcome these alloresponses, ex vivo T-cell depletion per-
mitted to reduce GVHD incidence but opportunistic infections
were increased due to high level of immunodepression [2]. To
date, numerous studies including a variety of hematological
malignancies have evaluated the safety and effectiveness of
post-transplantation cyclophosphamide (PTCy) in unmanipu-
lated grafts, and reported considerable beneﬁts of this ther-
apeutic scheme in terms of low incidence of non-relapse
mortality (NRM) and low incidence of severe acute and
chronic GVHD [3–7]. Despite tremendous progresses in opti-
mizing treatment modalities, the in-depth immunosuppression
therapy creates a permissive territory for pathogens. Viral
reactivations such as cytomegalovirus (CMV) or Epstein–Barr
virus (EBV), bacteremia, fungal and parasitic infections are
classically described after allogeneic stem cell transplantation
(alloSCT) [8]. Currently, data on infectious complications are
still limited and are mostly documented as secondary end
points during HaploSCT [2, 4, 7, 9–11]. In this study, we
retrospectively and particularly assessed the incidence of
infectious complications after HaploSCT with PTCy without
ex vivo T-cell depletion in a large cohort of 381 patients.
Patients and methods
This study was approved by the SFGM-TC board and
conducted in agreement with the declaration of Helsinki.
Informed consent was obtained from all subjects. Clinical
data were obtained through ProMISe (Project Manager
Internet Server), from 29 French centers and one Belgian
center.
Study design, inclusion criteria and data collection
This was a registry-based retrospective multicenter study
including patients 18 years or above who underwent Hap-
loSCT between January 2013 and December 2015. Patients
younger than 18 years at transplantation and those with non-
hematological malignancies were excluded. Referring local
physicians were asked to conﬁrm the diagnosis, clinical
history, treatment lines, disease status at the time of Hap-
loSCT, data on the HaploSCT, outcomes including GVHD
grading and infectious complications, and an updated
follow-up.
Conditioning, transplant modalities and prophylaxis
Peripheral blood stem cells (PBSC) (73%) or bone marrow
(BM) (27%) were used as stem cell source for transplan-
tation with no ex vivo T-cell depletion. Patients received
either a myeloablative (MAC) or a reduced-intensity con-
ditioning (RIC) regimen according to their age and
comorbidity, center’s practices and disease stage. Most
patients were treated with a RIC (81%) with a majority of
Baltimore scheme [4]. GVHD prophylaxis consisted of
high-dose cyclophosphamide (50 mg/kg) administered on
days +3 and +4 after Haplo, in combination with an
anticalcineurin and mycophenolate mofetil starting on day
+5. No thymoglobulin was used in this cohort. The median
total nucleated cell count was 7 × 108/kg (4–10), and the
median CD34+ cell count was 5 × 106/kg (3–7). Diagnosis
strategies for individual pathogens, particularly viral and
fungal infections, varied between centers based on local
laboratory practices. Infection prophylaxis was performed
according to institutional standard practice or were based on
recommendations [12]. In short, all patients received large
antimicrobial prophylaxis combining antifungal, antibiotic,
antiviral and antiparasitic agents: a β-lactam-based pro-
phylaxis for pneumococci and encapsulated bacteria starting
after aplasia, acyclovir or valacyclovir to prevent herpes and
varicella infections, cotrimoxazole or atovaquone for
Pneumocystis infections, ﬂuconazole for fungal infections
or posaconazole in case of GVHD.
Deﬁnitions
Neutrophil engraftment was deﬁned as achieving absolute
neutrophil count (ANC) ≥0.5 × 109/L for 3 consecutive
days, and platelet engraftment was deﬁned as achieving
platelet count ≥20 × 109/L unsupported by platelet transfu-
sions for 7 days. Acute GVHD (aGVHD) and chronic
GVHD (cGVHD) were deﬁned per published criteria
[13, 14].
Infection data were collected retrospectively by each
investigator, from conditioning until the patient’s death or
last follow-up. Infectious complications were deﬁned by a
systemic inﬂammatory response syndrome associated with a
microbiologically (blood culture collection, collection of
culture sample from any site with suspect infection) or/and
clinically and/or radiologically documentation (chest X-ray,
scanner, magnetic resonance imaging and so on). A fever
not explained by a non-infectious cause was also analyzed.
Infectious complications were speciﬁed as follows. (i) A
severe bacterial infection was deﬁned as bacteremia by any
bacterial organism, in a febrile patient. Bacterial infections
were divided into early (occurring within the ﬁrst 30 days
post-transplant) and late infections (occurring beyond day
30). (ii) CMV infection was deﬁned as the presence of a
single pp65 antigen-positive leukocyte or a positive viremia
in peripheral blood, as well as documentation of CMV
disease without prior positive antigenemia or viremia. CMV
disease was deﬁned as the demonstration of CMV in biopsy
or autopsy specimens from clinically involved visceral sites
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by culture and/or histology, or if CMV was detected in
culture (conventional or shell-vial) of bronchoalveolar
lavage samples in the presence of new or changing pul-
monary inﬁltrates. (iii) BK virus, human herpesvirus-6
(HHV-6) or EBV infection viremia testing were based on a
quantitative PCR method of viral DNA copies/mL. (iv)
Invasive fungal infections were divided in invasive asper-
gillosis, candidemia and other mycoses. Invasive aspergil-
losis gathered possible event (clinical signs and symptoms
plus a compatible thoracic computed tomography scan or
X-ray), probable event (clinical signs and symptoms,
compatible X-ray ﬁndings plus a positive respiratory tract
culture for Aspergillus spp.) and deﬁnite event (positive
histology for an invasive mold infection by aspergillus). (v)
Pneumonia of unknown origin was deﬁned as any new
radiological lung inﬁltrate in a febrile patient with respira-
tory symptoms in the absence of a known pathogen or
another evident diagnosis. This set of deﬁnitions was used
by all participating centers, according to the Infectious
Disease Working Party of the European Group for Blood
and Marrow Transplantation.
Statistical analysis
Median values and ranges were used for continuous vari-
ables and percentages as well as frequency for categorical
variables. Survival times were measured from the date of
the graft infusion to the date of event or the date of last
contact (censored data). Grade II–IV aGVHD and cGVHD,
infections as well as CMV reactivation were calculated
using the cumulative incidence (CI) methods Engraftment
and relapse were estimated using proportions. Relapse and
death from any cause were considered events. Statistical
analyses were performed with R software (3.2.5) and R
packages survival.
Results
Patients, disease and transplant characteristics
Patients and disease characteristics are summarized in
Table 1. A total of 381 patients were included between
January 2013 and December 2015. Patients were trans-
planted for acute myeloid or lymphoid leukemia or mye-
lodysplastic syndrome (n= 208), myeloproliferative disease
(n= 31), Hodgkin or non-Hodgkin’s lymphoma (n= 115),
multiple myeloma (n= 15), chronic leukemia (n= 10) and
bone marrow failure syndrome (n= 2). Thirty-seven per-
cent of patients had received at least a previous HSCT (68
autologous and 65 allogeneic). The median age at trans-
plantation was 55.7 years (38.7–62.8). Most of the patients
(65%) underwent HaploSCT in partial or complete remis-
sion. The type of conditioning varied according to the dis-
ease. Donor CMV seronegativity (D-CMV−)/recipient
CMV seronegativity (R-CMV−) was recorded in 122 cases
(32.0%), and in 250 cases (65.6%), D-CMV+ and/or R-
CMV+ was present. Complete data on CMV serostatus
were unavailable for 9 cases (2.4%).
Overall outcomes
Median follow-up of the cohort was 8.5 months (Q1–Q3,
3.7–19.3; range, 0.07 to 52.5). Median follow-up of
Table 1 Characteristics of patients in the study group (N= 381)
Characteristics Value





Acute leukemia/myelodysplatic syndrome 208 (54.6)
Hodgkin or non-Hodgkin’s lymphoma 115 (30.2)
Myeloproliferative disease 31 (8.1)
Multiple myeloma or solitary plasmacytoma 15 (3.9)
Chronic leukemia 10 (2.6)
Bone marrow failure syndrome 2 (0.5)
Median interval from diagnosis to transplantation, months
(range)
19.5 (7.7–38.5)
Previous transplant 143 (37.6)
Autologous 78
Allogeneic 65
Disease status at transplantation











Unknown pair 9 (2.7)







CD34+ cells, 106/kg (range) 5.1 (3.4–7.3)
CD3+ cells, 107/kg (range) 19.5 (5.21–29.7)
Values are total number of cases with percent in parentheses, unless
otherwise noted
BM bone marrow, CR complete remission, D donor, PBSC peripheral
blood stem cell, MAC myeloablative conditioning, PD progressive
disease, CMV cytomegalovirus, PR partial remission, R recipient, RIC
reduced-intensity conditioning, SD stable disease, VGPR very good
partial response
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surviving patients was 16.5 months (range, 5.3–24.9) and
median follow-up of patients who survived without relapse,
graft failure or new malignancy was 17.1 months (range,
5.3–25.5). While a total of 350 patients (92%) achieved an
absolute neutrophil count of 0.5 × 109/L in a median of
20 days (17–23), 296 patients (77.7%) achieved an
untransfused platelet count of 20 × 109/L in a median time
of 25 days (18–32). At day 35, 360 patients were evaluable
and 4 graft failures were observed (1%). CI of acute grade
II–IV and grade III–IV GVHD was 31.4% and 11.5% at day
+100, respectively; cGVHD was 48.2% at 50 months. The
median overall survival (OS) was 33.5 months and the
median progression-free survival (PFS) was 19.9 months.
The median GVHD-free and relapse-free survival (GRFS)
was 7.1 months (95% CI, 6.1–10.8). Transplant-related
mortality was of 11% (95% CI, 7.7–14.1) and 24% (95%
CI, 19.3–28.8) at day +100 and day +365 post transplan-
tation, respectively. During the follow-up period, 149
patients (39.1%) died, of which 82 patients (55.0%) were
relapse-free. The most common cause of deaths was related
to the HSCT procedure (55.6%), followed by relapse or
progression of the original disease (34.2%). For 10.2% of
patients, causes of death remained unknown. Infections (n
= 37) were the primary or contributing cause of
transplantation-related deaths: 45.9% (n= 17) were of
bacterial origin, 18.9% (n= 7) multiple infectious origins,
16.2% (n= 6) viral, 10.8% (n= 4) fungal and 8.1% (n= 3)
parasitic. CI of infection-associated treatment-related mor-
tality was 22.4% at 1 year post transplantation. CI of relapse
was 38.2% at the end of the study. Data from engraftment,
chimerism and HaploSCT-related toxicities and outcomes
are summarized in Table 2.
Infectious complications
At the last follow-up, a total of 1058 infectious episodes
were diagnosed using microbiological and/or clinical cri-
teria (Table 3). About 15% of the cases were not micro-
biologically documented, but clinically documented, and
only 3% of fever episodes were reported without clinical
manifestations and/or microbiological documentation.
Three hundred and forty-four patients (90.3%) experienced
at least one infection, with a median of 2 events/patients (1–
4) and a median onset to ﬁrst infection of 13 days (6–27).
Two hundred and thirty-two patients (67%) presented a
complication after day +20. Around 45% of the patients
experienced more than 2 infections, with 60 patients having
more than 5 episodes. Median time to ﬁrst infection was
13 days for bacterial, 32 days for viral and 20 days for
fungal infections. CI of ﬁrst infectious complications,
including clinical infections, was 90.6% at 12 months,
57.4% for bacterial and 61.4% for viral infections. CI of
ﬁrst and documented infections was 83% at 12 months
(Fig. 1a). Among the 1058 reported episodes, the most
common sites were bloodstream (54%), respiratory tract
(15%), urinary tract (10%), digestive tract (7%) and skin
(4%). Among the 113 patients with aGVHD grade II–IV, 41
patients (36%) experienced infectious complications,
whereas 56 patients (21%) with no signs of GVHD devel-
oped infections after day +30. Incidence of infection per
1000 patient-days was subdivided by standard periods of
infectious risk. Bacterial infections mostly occurred before
day +30, whereas viremia (viral infection or reactivation)
was predominant between day +30 and day +100 (Fig. 1b).
Among the 1022 infectious episodes with details on the
timing, 55 events (5.38%) manifested after 1 year post
transplantation.
Bacterial infections
As a ﬁrst complication, 157 patients (45.6%) experienced a
bacterial infection, with a total of 438 bacterial infections
Table 2 Engraftment, chimerism, HaploSCT-related toxicities and
outcomes (N= 381)
Characteristics Value
Time to engraftment (days, (range))
ANC > 0.5 × 109/L (N= 354) 20 (17–23)








Grade II–IV 107 (94.7)












Values are total number of cases with percent in parentheses, unless
otherwise noted
HaploSCT haploidentical stem cell transplantation, aGVHD acute
GVHD, ANC absolute neutrophil count, CR complete remission,
GVHD graft-vs.-host disease, PLT platelet, PD progressive disease, PR
partial remission, SD stable disease, VGPR very good partial response
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(41.3% of total infections) during the follow-up period.
Gram-negative bacilli were the most prevalent micro-
organisms (59.3%) with a majority of Enterobacteriaceae.
Staphylococcus species were responsible for 66% of
infections by Gram-positive cocci (32.2% of bacterial
infections), with a predominance of coagulase-negative
staphylococci (61.7%). In addition, 33 cases of infections
related to Enterococcus species and 14 related to Strepto-
coccus species were also reported. A total of 36 Gram-
positive bacilli infections were identiﬁed, 31 were related to
Clostridium difﬁcile. After day +30, majority of bacterial
infections (66%) are due to Gram-negative bacteria.
Viral infections
A total of 375 viral infections (35.4% of total infections)
were reported. CMV reactivation was noticed in 122
patients (48.8%). Median time of CMV reactivation was
39 days (27–52). The CI of CMV reactivation by day +200
was 61.2% in D-CMV−/R-CMV+, 54.7% in D-CMV+/R-
CMV+ and 31.2% in D-CMV+/R-CMV−. Seventeen
patients (4.5%) experienced CMV-associated disease,
affecting the gut in 6 cases and 11 pneumonias. BK virus
(BKV)-related hemorrhagic cystitis (HC) accounted for
18.1% of viral infections. Median onset of BK virus was
41 days (range, 29–41). We also reported 65 episodes of
HHV-6 reactivations, and 30 for EBV, 11 infections related
to varicella-zoster virus (VZV), 9 related to respiratory
syncytial virus and herpes simplex virus, 8 related to par-
vovirus and 6 related to adenovirus. Further detail is pro-
vided for other viruses in Supplementary Table 1.
Fungal and parasitic infections
Fungal infections were diagnosed in 78 patients with a
median occurrence of 20 days from HaploSCT (13–60).
Invasive aspergillosis was the most common infection
(43.6%), followed by invasive candidiasis (33.3%) and
pneumocytosis (12.8%). Additionally, 8 parasitic infections
with Toxoplasma gondii were reported. A detailed overview
of these infective epidodes is provided in Supplementary
Table 1.
Discussion
The present analysis describes the amount of infectious
complications on hematological patients transplanted with
unmanipulated haplo receiving PTCy as GVHD prophy-
laxis. So far, our study has included the largest cohort of
over 350 patients with a multicenter experience, thereby
providing additional information on detailed infectious
complications to previously published reports. To date, lit-
erature data with a special focus on infectious complications
are not thorough and usually they are limited to small
cohorts and monocentric experiences [2, 7, 9–11, 15].
HaploSCT has emerged as an option for patients who
lacked suitable human leukocyte antigen (HLA)-matched
donor, but complications are the most common causes of
morbidity and mortality. It is also known that the extent of
mismatch disparity correlates with the rate of infections, in
the allogeneic HSCT setting [16, 17]. More importantly, we
Table 3 Infectious complications (N= 381)
Characteristics Value
Patients with infectious complications
Yes 344 (90.3)
No 37 (9.7)
Total number of infections 1058
Median number of infectious complications/patient (n
(range))
2 (1–4)
Number of infectious complications/patient
1 to 2 172 (45.1)
3 to 5 112 (29.4)
>5 60 (15.7)






















Parasitic infectionsa 8 (0.8)
Nondocumented 159 (15)
Values are total number of cases with percent in parentheses, unless
otherwise noted
BKV BK virus, CMV cytomegalovirus, HHV-6 human herpesvirus-6,
EBV Epstein–Barr virus, VZV varicella-zoster virus
aFor Toxoplasma gondii
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found that 90% of the patients experienced at least one
infection and these complications were a primary or con-
tributing cause of death for less than half of the patients who
died in the follow-up period. Not surprisingly, bacteria were
the leading responsible pathogens during the pre-
engraftment phase, whereas viral infections were pre-
dominant in the early post-engraftment period. Our results
are in line with previous reports in the setting of HaploSCT
or HLA-matched transplants [2, 4, 7, 9–11, 18–20]
(Table 4). An inherent aspect of retrospective studies is the
lack of exhaustiveness of collected data, especially during
the follow-up period. This might largely explain the low
rate of infectious diseases after day 100 as these events were
not systematically reported.
Neutrophil recovery is an important factor determining the
risk of bacterial infections after allo-HSCT. Indeed, approxi-
mately 30% of the patients have a bacterial infection, most
























































Fig. 1 First Infectious complications following haploidentical transplantation with post-transplantation cyclophosphamide. a Cumulative incidence
of documented infections by pathogen type. b First infection rates at different post-transplant intervals by pathogen type
Table 4 Review of the literature:
infectious complications in the




Luznik et al. [4] 68 Graft, BM
Cond, MAC
26% CMV reactivation, 7% IFI
Ciurea et al. [2] 32 Graft, BM 97%
Cond, MAC 81%
35% Bacterial infections, 55% viral infections, 47% CMV
reactivation, 34.4% BK, 9% IFI
Raiola et al. [7] 50 Graft, BM
Cond, MAC
50% CMV reactivation, 4% CMV-associated disease, 40%
HC, 26% BK, 18% IFI
Castagna et al.
[11]
69 Graft, BM 67%
Cond, MAC
41% Bacterial infections, 41% CMV reactivation, 7% HC
Crocchiolo et al.
[9]
70 Graft, BM 94%
Cond, NMA
68%
40% Bacterial infections, 55% viral infections, 50% CMV
reactivation, 4% CMV-associated disease, 19% HC, 14%
BK, 5% IFI
Slade et al. [10] 104 Graft, PBSC
Cond, NMA
59%
46% Bacterial infections, 52% viral infections, 55% CMV
reactivation, 15% CMV-associated disease, 19% HC, 32%
BK, 2.2% IFI
Fayard et al. 381 Graft, PBSC
73%
Cond, RIC 81%
40.9% Bacterial infections, 34.1% viral infections, 34.1%
CMV reactivation, 4.5% CMV-associated disease, 18% HC,
18% BK, 6.1% IFI
These studies documented the rate of various infectious complications, with either a general interest on
global infectious complications or a special focus on some speciﬁc pathogens
BK BK virus, BM bone marrow, charac. characteristics, Cond conditioning, CMV cytomegalovirus,
HaploSCT haploidentical stem cell transplantation, HC hemorrhagic cystitis, IFI invasive fungal infection,
MAC myeloablative conditioning, NMA non-myeloablative, PBSC peripheral blood stem cell, PTCy post-
transplantation cyclophosphamide, RIC reduced-intensity conditioning
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staphylococci [21]. We found a rate of 40.9% of bacterial
infections as well as 57.4% CI at 12 months, with a peak in
the day 0 to day 30 period at a rate of approximately 18.2 per
1000 patient-days. Of note, the rate of bacterial infections
found here was comparable to the 40–46% reported in ana-
logous haploidentical settings. Slade et al. [10] described a
similar overall rate of bacterial infections and reported a
slightly lower incidence within the ﬁrst 30 days of about 14
events per 1000 patient-days. In the cohort of 70 patients from
Crocchiolo et al. [9], the rate of bacterial infections was about
40% with approximately 11 per 1000 patients-days during
this speciﬁc period. The higher incidence of early bacterial
infections that we found here may be explained by differences
in routine bacterial prophylaxis that has been administered
according to center’s practices.
Regarding viral infections, we observed a remarkable
lower rate of viral infections (34.1%) as compared to pre-
vious publications that reported rates of about 52–55% [2,
9, 10]. Yet, the overall rate was in accordance with those
related to allo-HSCT that account for 20 to 30% of all
infections [18]. Consistent with the fact that viral infection
was more prominent in the early post-engraftment period
[10], we also noticed that virus accounted for around 50%
of infectious complications after day +20. In addition, in
our series, the CI of viral infections at 12 months (61.4%)
was lower than in previous literature (vs. 77% in Crocchiolo
et al. [9] and about 80% in Slade et al. [10]). This incidence
is probably underestimated considering the high incidence
of cGVHD and it might be explained by a non-extensive
reporting after day +100.
Among the viral infections, CMV reactivation and
human polyomavirus BK cystitis were the most frequent.
The 34.1% of CMV reactivations, with 4.5% of CMV-
associated diseases, coincided with the 21–34% reported in
alloSCT settings [18, 22]. In the context of HaploSCT, one
can depict variable incidences of CMV reactivations,
varying from 26% [4] up to 55% [2, 9–11]. One possible
explanation is the absence of documented threshold that
deﬁnes viral load requiring treatment initiation, given that
this aspect might differ according to centers. The hetero-
geneity in the donor/recipient CMV serological status due
to geographical and ethnological characteristics has also to
be taken into account. We also noticed that 18% of patients
developed BKV-associated HC. In our cohort, only symp-
tomatic BK reactivations are described. This complication
usually occurs in 20–60% of HSCT recipients according to
the different studies [23–27]. The low incidence of HC in
this population was noteworthy compared to other studies
[2, 7] and higher incidence in the literature is due to BK
reactivation without symptoms. It has been previously
shown that the conditioning regimen is an important factor
for the development of HC [25, 26]. Moreover, it has also
been proven that cyclophosphamide use and alternative
donors favor the occurrence of HC [27]. It cannot be
ignored that the vast majority of these patients received a
RIC regimen, suggesting that the incidence of HC is
probably biased by this parameter. Therefore, further pro-
spective monitoring of BK viruria together with evaluations
of immune reconstitution after transplantation is likely to
deeply discern this complication.
Fungal infections remain an important cause of morbidity
and mortality among patients undergoing allo-HSCT, with
an incidence ranging from 6 to 10%, and are associated with
high mortality rates (33%) [28, 29]. Invasive aspergillosis
has a high prevalence (80% from total invasive fungal
infections), whereas invasive candidiasis (11%), zygomy-
cosis (4%) and fusariosis (2%) are less observed [8]. Despite
a prolonged immunosuppression with PTCy, we observed
an incidence of fungal infections of about 6%, among which
half were related to Aspergillus species. These results were
into the range of previous reports [4, 9, 10].
Several groups have conducted retrospective studies to
compare outcomes from haploidentical transplants with PTCy
to other transplants platforms, including HLA-matched, mis-
matched unrelated donors and umbilical cord blood as the
donor source [30, 31]. Overall, these reports showed
equivalent outcomes between allo-HSCT and alternative
donor transplantation approaches. As to NRM, it appears to
vary depending on the studies, ranging from 8 to 30%, in the
context of HaploSCT [32]. It is noticeable that NRM asso-
ciated to infections is estimated up to 20% [31]. Thus, we can
describe similar NRM and infection-related NRM, even if
heterogeneity for these parameters is still questionable as a
consequence of the inclusion of patients with diverse disease
stages and because of variable rates of cGVHD.
Our cohort is currently the largest cohort that described
infectious complications after HaploSCT with PTCy. Yet,
our retrospective study is somehow limited, especially
regarding the availability of accurate documentation and the
absence of detailed immune reconstitution. Moreover, most
patients received RIC regimen which might be less prone to
infection risks. In this context, it would be necessary to
conduct a prospective study comparing the incidence of
infectious complications after HaploSCT vs. related or
unrelated allo-HSCT, in patients who received a similar
conditioning regimen. The lack of data exhaustiveness,
about the immune reconstitution proﬁle, as well as the
heterogeneity of the viral infections with various sig-
niﬁcance thresholds, are also weak points. Therefore, fur-
ther studies with standardized conditions would be required
to better document these variables.
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